Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Feb;8(2):147-54.

Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents

Jeffrey M Sobell  1 , Robert E Kalb, Jeffrey M Weinberg
Affiliations
  • PMID: 19213230
Review

Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents

Jeffrey M Sobell et al. J Drugs Dermatol. 2009 Feb.

Abstract

Psoriasis is an immunologic disorder mediated by T cells and proinflammatory cytokines. Novel biologic therapies, targeted at key pathogenic steps, have been developed and provide efficacy without the potential end-organ toxicity induced by traditional therapies. The biologic therapies currently approved for treatment of psoriasis are classified into 2 categories, as defined by their mechanism of action: inhibition of tumor necrosis factor (TNF) (etanercept, infliximab, adalimumab) and modulation of pathogenic activated T cells (alefacept, efalizumab). This review has been prepared in 2 parts: Part 1 focuses on anti-TNF agents and includes new data that have become available through increased clinical experience and use in eligible patients. Part 2 will present new data on T-cell modulators, new molecules in development, and considerations for optimal therapeutic selection for treatment of patients with psoriasis (Journal of Drugs in Dermatology, March 2009).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

MeSH terms

Substances

LinkOut - more resources